High expression of CD7 on CD34⁺ cells is not linked to deletion of derivative chromosome 9 or lack of dendritic cells in chronic myeloid leukaemia

References

• Groffen J., Heisterkamp N. The chimeric BCR‐ABL gene. Baillières Clin Haematol 1997; 10: 187–201
   PubMedGoogle Scholar
• Goldman J. M. Treatment of chronic myeloid leukaemia: some topical questions. Baillières Clin Haematol 1997; 10: 405–21
   Google Scholar
• Sokal J. E., Cox E. B., Baccarani M., Tura S., Gomez G. A., Robertson J. E., et al. Prognostic discrimination in “good‐risk” chronic granulocytic leukemia. Blood 1984; 63: 789–99
   PubMed Web of Science ®Google Scholar
• Hasford J., Pfirrmann M., Hehlmann R., Allan N. C., Baccarani M., Kluin‐Nelemans J. C., et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998; 90: 850–8
   PubMed Web of Science ®Google Scholar
• Hehlmann R., Heimpel H., Hasford J., Kolb H. J., Pralle H., Hossfeld D. K., et al. Randomized comparison of interferon‐alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood 1994; 84: 4064–77
   PubMedGoogle Scholar
• Deininger M. W. Management of early stage disease. Hematology/the Education Program of the American Society of Hematology. Am Soc Hematol 2005; 174–82
   Google Scholar
• Normann A. P., Egeland T., Madshus I. H., Heim S., Tjonnfjord G. E. CD7 expression by CD34+ cells in CML patients, of prognostic significance?. Eur J Haematol 2003; 71: 266–75
   PubMed Web of Science ®Google Scholar
• Yong A. S., Szydlo R. M., Goldman J. M., Apperley J. F., Melo J. V. Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML. Blood 2006; 107: 205–12
   PubMed Web of Science ®Google Scholar
• Martin‐Henao G. A., Quiroga R., Sureda A., Garcia J. CD7 expression on CD34+ cells from chronic myeloid leukaemia in chronic phase. Am J Hematol 1999; 61: 178–86
   PubMedGoogle Scholar
• Steen R., Tjonnfjord G. E., Egeland T. Comparison of the phenotype and clonogenicity of normal CD34+ cells from umbilical cord blood, granulocyte colony‐stimulating factor‐mobilized peripheral blood, and adult human bone marrow. J Hematother 1994; 3: 253–62
   PubMedGoogle Scholar
• Tjonnfjord G. E., Steen R., Evensen S. A., Thorsby E., Egeland T. Characterization of CD34+ peripheral blood cells from healthy adults mobilized by recombinant human granulocyte colony‐stimulating factor. Blood 1994; 84: 2795–801
   PubMed Web of Science ®Google Scholar
• Mohty M., Isnardon D., Vey N., Briere F., Blaise D., Olive D., et al. Low blood dendritic cells in chronic myeloid leukaemia patients correlates with loss of CD34+/CD38‐primitive haematopoietic progenitors. Br J Haematol 2002; 119: 115–18
   PubMed Web of Science ®Google Scholar
• Boissel N., Rousselot P., Raffoux E., Cayuela J. M., Maarek O., Charron D., et al. Defective blood dendritic cells in chronic myeloid leukemia correlate with high plasmatic VEGF and are not normalized by imatinib mesylate. Leukemia 2004; 18: 1656–61
   PubMedGoogle Scholar
• Sinclair P. B., Nacheva E. P., Leversha M., Telford N., Chang J., Reid A., et al. Large deletions at the t(9;22) breakpoint are common and may identify a poor‐prognosis subgroup of patients with chronic myeloid leukemia. Blood 2000; 95: 738–43
   PubMed Web of Science ®Google Scholar
• Huntly B. J., Reid A. G., Bench A. J., Campbell L. J., Telford N., Shepherd P., et al. Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood 2001; 98: 1732–8
   PubMed Web of Science ®Google Scholar
• Kolomietz E., Al‐Maghrabi J., Brennan S., Karaskova J., Minkin S., Lipton J., et al. Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis. Blood 2001; 97: 3581–8
   PubMed Web of Science ®Google Scholar
• Cohen N., Rozenfeld‐Granot G., Hardan I., Brok‐Simoni F., Amariglio N., Rechavi G., et al. Subgroup of patients with Philadelphia‐positive chronic myelogenous leukemia characterized by a deletion of 9q proximal to ABL gene: expression profiling, resistance to interferon therapy, and poor prognosis. Cancer Genet Cytogenet 2001; 128: 114–19
   PubMed Web of Science ®Google Scholar
• Huntly B. J., Bench A. J., Delabesse E., Reid A. G., Li J., Scott M. A., et al. Derivative chromosome 9 deletions in chronic myeloid leukemia: poor prognosis is not associated with loss of ABL‐BCR expression, elevated BCR‐ABL levels, or karyotypic instability. Blood 2002; 99: 4547–53
   PubMed Web of Science ®Google Scholar
• Fourouclas N., Campbell P. J., Bench A. J., Swanton S., Baxter E. J., Huntly B. J., et al. Size matters: the prognostic implications of large and small deletions of the derivative 9 chromosome in chronic myeloid leukemia. Haematologica 2006; 91: 952–5
   PubMed Web of Science ®Google Scholar
• Huntly B. J., Bench A., Green A. R. Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia. Blood 2003; 102: 1160–8
   PubMed Web of Science ®Google Scholar
• Mitelman F. An international system for human cytogenetics nomenclature. S. Karger, Basel 1995
   Google Scholar
• Olweus J., BitMansour A., Warnke R., Thompson P. A., Carballido J., Picker L. J., et al. Dendritic cell ontogeny: a human dendritic cell lineage of myeloid origin. Proc Natl Acad Sci USA 1997; 94: 12551–6
   PubMed Web of Science ®Google Scholar
• O'Doherty U., Peng M., Gezelter S., Swiggard W. J., Betjes M., Bhardwaj N., et al. Human blood contains two subsets of dendritic cells, one immunologically mature and the other immature. Immunology 1994; 82: 487–93
   PubMed Web of Science ®Google Scholar
• Allan N. C., Richards S. M., Shepherd P. C. UK Medical Research Council randomised, multicentre trial of interferon‐alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet 1995; 345: 1392–7
   PubMed Web of Science ®Google Scholar
• Siegal F. P., Kadowaki N., Shodell M., Fitzgerald‐Bocarsly P. A., Shah K., Ho S., et al. The nature of the principal type 1 interferon‐producing cells in human blood. Science 1999; 284: 1835–7
   PubMed Web of Science ®Google Scholar